We report a patient with stiff-person syndrome and insulin-dependent diabetes mellitus with anti-glutamic acid decarboxylase (GAD) 
Introduction

Stiff-person syndrome (SPS) is a rare intractable disorder characterized clinically by progressive rigidity and episodic sudden-onset muscle spasms with frequent association of insulin-dependent diabetes mellitus (DM) and chronic thyroid disorders (1). The anti-glutamic acid decarboxylase (GAD) antibody plays an important role in the pathogenesis by affecting the synaptic transmission of inhibitory neurons, and SPS has come to be recognized as a B-cell-mediated autoimmune disorder of the central nervous system (1-3). To ameliorate clinical symptoms due to SPS, therefore, immunomodulatory therapies targeting the anti-GAD antibody, such as plasmapheresis and high-dose intravenous immunoglobulin (IVIg), are often employed for treatment
. Here i g u r e 2 . MRI d e mo n s t r a t e d h y p e r t r o p h y wi t h e n h a n c eme n t e f f e c t s i n o c u l a r mu s c l e s , p a r t i c u l a r l y i n t h e l e f t s u p er i o r r e c t u s ( a r r o w) , b e f o r e t r e a t me n t ( A, T 1 -we i g h t e d i ma g e wi t h g a d o l i n i u m e n h a n c e me n t , T R/ T E = 6 0 0 / 9 . 4 ) . T h e s e a b n o rma l f i n d i n g s ma r k e d l y i mp r o v e d 3 mo n t h s a f t e r t h e r i t u x ima b t h e r a p y ( B , T 1 -we i g h t e d i ma g e wi t h g a d o l i n i u m e nh a n c e me n t , T R/ T E = 6 0 0 / 9 . 4 ) . (Fig. 3B) and clinical activity score of dysthyroid ophthalmopathy (Fig. 3C) following quick complete depletion of CD20-positive cells in peripheral blood (Fig. 3A) . The anti-GAD antibody, TGAb and TPOAb decreased from approximately 6 weeks after the administration of rituximab (Figs. 3B, 3C) , while the TRAb showed no obvious change. (1, 4, 9) , we decided to use rituximab for treatment of the present patient. This drug is a humanized chimeric anti-CD20 monoclonal antibody capable of killing CD20-positive cells by complement-mediated cytotoxicity, antibodydependent cellular cytotoxicity and direct induction of apoptosis (10, 11) . CD20 is expressed on the surface of pre-Band mature B-lymphocytes (12) , and rituximab shows no direct effects on plasma cells producing immunoglobulins. This drug has been reported to show a favorable outcome in the treatment of malignant lymphoma and autoimmune diseases, including SPS and dysthyroid ophthalmopathy (9, (13) (14) (15) (16) (17) . In the present patient also, intermittent administrations of rituximab produced obvious improvement of both SPS and dysthyroid ophthalmopathy with a persistent decrease in the anti-GAD and anti-thyroid antibodies. According to the recommended therapeutic protocol for autoimmune disorders, including dysthyroid ophthalmopathy, rituximab is usually given twice at an interval of 2 weeks (13, 14) 
S p o n t a n e o u s mo t o r u n i t a c t i v i t y r e c o r d e d f r o m t h e r i g h t q u a d r i c e p s a t r e s t s h o we d i n v o l u n t a r y mu s c l e c o n t r a c t i o n ( A) , wh i c h d i s a p p e a r e d a f t e r i n t r a v e n o u s a d mi n i s t r a t i o n o f d i a z e p a m a t a d o s e o f 5 mg ( B ) .
R
F i g u r e 3 . Cl i n i c a l p r o f i l e s o f t h e p a t i e n t . Af t e r s t a r t i n g a d mi n i s t r a t i o n o f r i t u x i ma b , t h e p a t i e n t s h o we d o b v i o u s d e c r e a s e s i n t h e mu s c l e s t i f f n e s s s c o r e o f S P S ( B ) a n d c l i n i c a l a c t i v i t y s c o r e o f d y s t h y r o i d o p h t h a l mo p a t h y ( C) f o l l o wi n g q u i c k c o mp l e t e d e p l e t i o n o f CD2 0 -p o s i t i v e c e l l s i n p er i p h e r a l b l o o d ( A) . T h e a n t i -GAD a n d a n t i -t h y r o i d a n t i b o d i e s d e c r e a s e d s l o wl y ( B a n d C) .
MRI demonstrated reduction in size of ocular muscles with disappearance of gadolinium enhancement (Fig. 2B). Three months later rituximab was additionally given at the same dose as the first administration 2 times at an interval of 1 month because of a slight increase in the frequency of muscle spasms. The anti-GAD antibody, TGAb and TPOAb remained at low levels, and TRAb also decreased gradually. Five months after the third administration of rituximab mus-
